ANTITUMOR ANTIBIOTICS
·        
Interferes
with DNA synthesis by binding DNA; prevents RNA synthesis
·        
Indication:
o   
Target
malignancies: Leukemias, Neuroblastoma, Nephroblastoma, breast caner, ovarian
cancer, thyroid cancer and lung cancer
·        
Contraindication:
o   
Lung
disease, renal and hepatic disorders, ulcers, and gastrointestinal disease
| 
Example: | 
| 
bleomycin (Blenoxane®) | 
| 
dactinomycin (Actinomycin D®,
  Cosmegan®) | 
| 
daunorubicin (DaunoXome®,
  Cerubidine®)  | 
| 
doxorubicin (Adriamycin®) | 
| 
idarubicin (Idamycin®) | 
| 
mitomycin (Mutamycin®) | 
| 
mitoxantrone (Novantorone®) | 
| 
plicamycin (Mithracin®) | 
| 
valrubicin (Valstar®) | 
Side Effects:
·        
Bone
marrow suppression
·        
Nausea
and vomiting
·        
Alopecia
·        
Anorexia
·        
Vesication
·        
Daunorubicin
(DaunoXome), Idarubicin (Idamycin) and Doxorubicin (Adriamycin): cardiotoxicity
·        
Bleomycin
(Blenoxane): pulmonary toxicity
·        
Plicamycin
(Mithracin): affects bleeding time
Nursing Considerations:
ü  Assess vital signs and temperature for signs
of infection.
ü  Withhold medication if platelet count is
<75,000 cells/µL or WBC is <4000 cells/ µL and notify the physician.
ü  Monitor ECG; assess for arrhythmias, gallops
and CHF (during dactinomycin [Actinomycin D], daunorubicin [DaunoXome,
Cerubidine], Doxorubicin [Adriamycin] therapy.
ü  Monitor CBC with differential, BUN and uric
acid.
ü  Assess pulmonary function studies (during
Bleomycin [Blenoxane] therapy). 
ü  Assess for bleeding; check stool for occult
blood. Avoid use of aspirin, anticoagulants and thrombolytic agents (during
Plicamycin [Mithracin] therapy).
ü  May see delayed cardiotoxicity months to
years after administration of doxorubicin.
ü  To prevent heart failure related to
doxorubicin, do not administer more than 550 mg/m2  in a lifetime
ü  Evaluate hydration and nutrition status.
ü  Monitor IV site for vesication.
ü  Instruct oral care for stomatitis.
ü 
Teach
care for hair loss.
MITOTIC SPINDLE POISONS (Mitotic
Inhibitors, Vinca Alkaloids)
·        
Arrests
metaphase by inhibiting mitotic tubular formation (spindle); inhibit DNA and
protein synthesis
·        
Indication:
o   
Target
malignancies: Leukemias, Hodgkin’s and Non-Hodgkin’s lymphomas,lymphocytic and
histocytic lymphoma, neuroblastoma, nephroblastoma, Kaposi’s sarcoma, advanced
testicular cancer and unresponsive breast cancer  
·        
Contraindication: Cardiovascular, hepatic, nerve, and muscle
disease
| 
Example: | 
| 
Plant Alkaloids 
o    etoposide
  (VePesid®) 
o    teniposide
  (Vumon®) 
o    vinblastine
  (Velban®) 
o    vincristine
  (Oncovin®) 
o    vinorelbine
  (Navelbine®) | 
| 
Taxanes 
o    paclitaxel
  (Nov-Onxol®, Taxol®, Paclitaxel Novaplus®) 
o    docetaxel
  (Txotere®) | 
Side Effects:
·        
Alopecia
·        
Hoarseness
·        
Ptosis
·        
Anorexia,
nausea and vomiting
·        
Stomatitis
·        
Hyperuricemia
·        
Constipation,
paralytic ileus
·        
Vinblastine(Velban®):
bone marrow suppression
·        
Vincristine
(Oncovin®): Neorotoxicity/ neuropathies
·        
Taxanes:
Bradycardia, hypersensitivity reactions and neuropathies 
·        
Areflexia
Nursing Considerations:
ü 
Assess vital
signs.
ü 
Monitor
CBC with differential.
ü 
Assess
neuromuscular function.
ü 
Evaluate
gastrointestinal function; manage constipation.
ü 
Administer
antiemetics prn as ordered.
ü 
Monitor
eyes for ptosis; monitor for hoarseness.
ü 
Teach
ways to manage hair loss.
HORMONAL AGENTS
·        
Binds
to hormone receptor sites that alter cellular growth; block binding of
estrogens to receptor sites (antiestrogens); inhibit RNA synthesis
·        
Indication:
o   
Target
malignancies: Advanced breast and prostate cancer
·        
Contraindication:
o   
Pregnancy,
hepatic and renal disease, osteoporosis, hypertension, hypercholesterolemia 
| 
Example: | 
| 
diethylstilbestrol (DES, Stilphostrol®) | 
| 
letrozole (Femara®) | 
| 
raloxifene (Evista®) | 
| 
tamoxifen (Nolvadex®) | 
| 
goserilin acetate (Zoladex®) | 
| 
Testosterone | 
| 
medroxyprogesterone (Depo- Provera®) | 
| 
asparaginase (Elspar®) | 
| 
mitotane (Lysodren®) | 
| 
megestrol acetate (Megace®) | 
Side Effects:
·        
Hypercalcemia
·        
Hypertension
·        
Jaundice
·        
Increased
appetite, weight gain
·        
Masculinization
·        
Feminization
·        
Sodium
and fluid retention
·        
Hot
flashes
·        
Vaginal
dryness
·        
Nausea
and vomiting 
·        
Asparaginase
(Eslpar): impaired pancreatic function
·        
Mitotane
(Lysodren): Hemorrhagic cystitis, hyperuricemia and hypercholesterolemia 
·        
Tamoxifen
(Nolvadex): Edema, hypercalcemia, elevated cholesterol and triglyceride levels,
decreased effects of estrogen 
·        
Diethylstilbestrol
(DES, Stilphostrol):
§  Female: Fluid retention, feminization and
uterine bleeding
§  Male: impotence and masculinization 
Nursing Considerations:
ü 
Monitor
vital signs.
ü 
Administer
diuretics prn as ordered.
ü 
Monitor
for bleeding.
ü 
Monitor
electrolytes, uric acid and cholesterol levels.
ü 
Monitor
pancreatic function.
ü 
Explain
reason for sex characteristic alterations.
ü 
Provide
patient teachings for managing hot flashes.